• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Absci (ABSI) Shares Moved After A Fresh Update, What Is Behind It?

    Simply Wall St·10/24/2026 08:31:51
    Listen to the news

    ABS-201 trial update puts Absci’s clinical progress in focus

    Absci (ABSI) just reported interim Phase 1 results for ABS-201 in pattern hair loss, highlighting an estimated half-life of at least 65 days and setting a timeline for upcoming proof-of-concept data.

    For investors, the update matters because it gives an early read on how ABS-201 behaves in the body, while anchoring expectations around more detailed efficacy and safety results planned for the second half of 2026 and early 2027.

    Absci’s share price has swung around these trial headlines, with a 7 day share price return of 11.27% but a 30 day share price return down 5.8%. The year to date share price return of 154.29% and a 3 year total shareholder return above 6x point to strong longer term momentum.

    Scan 34 healthcare AI stocks to see how other AI-driven drug discovery players compare with Absci after this ABS-201 trial update.

    After a 3 year return above 6x and a year to date gain above 150%, Absci now trades on a very different footing. Does the current risk reward still lean toward buyers, or has the easy upside already been taken?

    Most Popular Narrative: 38% Undervalued

    Absci closed at $9.18, while the most widely followed narrative pegs fair value at $14.90. The market is pricing in a wide gap that only makes sense if the ABS-201 plan and broader platform story play out as outlined.

    Advancement of ABS-201 toward two proof of concept readouts in androgenetic alopecia and endometriosis over the next 24 months positions Absci to convert large underpenetrated markets into meaningful revenue growth and improved earnings power.

    See why 15 investors see Absci as 38% undervalued.

    Result: Fair Value of $14.90 (UNDERVALUED)

    Still, the bullish Absci story hinges on ABS-201 clearing key efficacy and safety hurdles, and on management actually securing meaningful AI drug creation partnerships.

    Find out about the key risks to this Absci narrative.

    Next Steps

    If this combination of optimism and risk around Absci leaves you undecided, consider stress testing the thesis against the full picture of 1 key reward and 3 important warning signs.

    Looking for more Absci-sized ideas to research next?

    Do not stop with Absci. Broaden your watchlist now and you will give yourself a better shot at spotting the next opportunity before it feels obvious.